4//SEC Filing
RENSCHLER MARKUS MD 4
Accession 0001209191-23-007494
CIK 0001662244other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 4:08 PM ET
Size
7.7 KB
Accession
0001209191-23-007494
Insider Transaction Report
Form 4
RENSCHLER MARKUS MD
DirectorSee Remarks
Transactions
- Award
Common Stock
2023-01-13$1.49/sh+5,000$7,450→ 983,736 total - Award
Stock Option (Right to Buy)
2023-02-03+302,600→ 302,600 totalExercise: $1.69Exp: 2033-02-03→ Common Stock (302,600 underlying)
Footnotes (2)
- [F1]The reporting person is voluntarily reporting the acquisition of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"), for the ESPP purchase period of July 15, 2022 through January 13, 2023. This transaction is also exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price January 13, 2023, the last trading day of the purchase period.
- [F2]The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.
Documents
Issuer
Cyteir Therapeutics, Inc.
CIK 0001662244
Entity typeother
Related Parties
1- filerCIK 0001217598
Filing Metadata
- Form type
- 4
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 4:08 PM ET
- Size
- 7.7 KB